Condition: Cholestatic Liver Disease · Sponsor: Zydus Therapeutics Inc.
Evaluating Pharmacokinetic and safety of Saroglitazar Magnesium 1 mg when dosed on alternate days in subjects having moderate hepatic impairment with cirrhosis due to cholestatic liver disease
This description comes directly from the study's public registry record.
Farheen Shaikh · +1-609-453-4751 · fshaikh@zydustherapeutics.com
Deven Parmar · +1-609-946-9340 · dparmar@zydustherapeutics.com
Always discuss trial participation with your own doctor first.
| Zydus Site US001 | Indianapolis, Indiana, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06825559